• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    INVO Bioscience Announces Birth From INVOcell

    Bryan Mc Govern
    Sep. 25, 2017 08:39AM PST
    Medical Device Investing

    INVO Bioscience announced the birth of the first two babies conceived through the INVOcell technology.

    INVO Bioscience (OTC:IVOB) announced the birth of the first two babies conceived through the INVOcell technology.
    As quoted in the press release:

    Marin Fertility Center has been offering the INVOcell and INVO procedure since late 2016, when the twins were conceived. Dr. Peter Uzelac, a reproductive endocrinologist said, “This technology simplifies the IVF process, driving down the cost to make it more accessible to patients that would not otherwise be able to afford care.”
    The mother of the twins, a 30-year-old woman, had tubal factor infertility and had been trying for two years to conceive. Dr. Jennifer Agard, a reproductive endocrinologist with Marin Fertility Center since 2015, was the lead doctor treating the patient looking for a more cost-effective alternative to traditional IVF.
    “INVO Bioscience is delighted to have Marin Fertility Center furthering our mission in California to provide affordable, safe and effective treatment for infertility,” said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. “Drs. Uzelac and Agard, along with the team at Marin Fertility Center, were early adopters of the INVOcell Intravaginal Culture System, and we share in the joy of family building for these deserving patients.”

    Click here to read the full press release. 

    Source: www.accesswire.com

    invo biosciencemedical device investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU

    Bloom Health Partners

    BLMH:CNX

    Applied UV

    AUVI:NSD

    Beyond Medical Technologies

    DOCT:CNX

    Avricore Health

    AVCR:CA

    Avisa Diagnostics

    AVBT:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×